skip to main content
Language:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Simple Search

Results 1 - 20 of 642  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Refined by: Database: HighWire Press (Free Journals) remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
The value of the veterinary professional
The value of the veterinary professional
Material Type:
Article 		Add to My Research

The value of the veterinary professional

Veterinary record, 2019-03, Vol.184 (13), p.415-415 [Peer Reviewed Journal]

British Veterinary Association ;British Veterinary Association 2019 ;British Veterinary Association2019 ;ISSN: 0042-4900 ;EISSN: 2042-7670 ;DOI: 10.1136/vr.l1384 ;PMID: 30926705

Full text available

Citations Cited by
2
POS0599 DISEASE ACTIVITY IN PATIENTS WITH RA BY SEROSTATUS AND TREATMENT LINE, FOLLOWING TREATMENT WITH ABATACEPT: RESULTS FROM AN INTERNATIONAL OBSERVATIONAL STUDY
POS0599 DISEASE ACTIVITY IN PATIENTS WITH RA BY SEROSTATUS AND TREATMENT LINE, FOLLOWING TREATMENT WITH ABATACEPT: RESULTS FROM AN INTERNATIONAL OBSERVATIONAL STUDY
Material Type:
Article 		Add to My Research

POS0599 DISEASE ACTIVITY IN PATIENTS WITH RA BY SEROSTATUS AND TREATMENT LINE, FOLLOWING TREATMENT WITH ABATACEPT: RESULTS FROM AN INTERNATIONAL OBSERVATIONAL STUDY

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.533-534 [Peer Reviewed Journal]

2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-eular.928

Full text available

Citations Cited by
3
AB0207 ANALYSIS OF ABATACEPT TREATMENT RETENTION AND EFFICACY ACCORDING TO DISEASE DURATION AND TREATMENT LINE IN A REAL-WORLD SETTING
AB0207 ANALYSIS OF ABATACEPT TREATMENT RETENTION AND EFFICACY ACCORDING TO DISEASE DURATION AND TREATMENT LINE IN A REAL-WORLD SETTING
Material Type:
Article 		Add to My Research

AB0207 ANALYSIS OF ABATACEPT TREATMENT RETENTION AND EFFICACY ACCORDING TO DISEASE DURATION AND TREATMENT LINE IN A REAL-WORLD SETTING

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.1128-1130 [Peer Reviewed Journal]

2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-eular.955

Full text available

Citations Cited by
4
AB0202 IMPROVEMENT IN CLINICAL DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES AFTER 6 MONTHS OF TREATMENT WITH ABATACEPT, STRATIFIED BY LINE OF THERAPY, IN PATIENTS WITH RA: RESULTS FROM A LARGE, US, NATIONAL OBSERVATIONAL STUDY
AB0202 IMPROVEMENT IN CLINICAL DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES AFTER 6 MONTHS OF TREATMENT WITH ABATACEPT, STRATIFIED BY LINE OF THERAPY, IN PATIENTS WITH RA: RESULTS FROM A LARGE, US, NATIONAL OBSERVATIONAL STUDY
Material Type:
Article 		Add to My Research

AB0202 IMPROVEMENT IN CLINICAL DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES AFTER 6 MONTHS OF TREATMENT WITH ABATACEPT, STRATIFIED BY LINE OF THERAPY, IN PATIENTS WITH RA: RESULTS FROM A LARGE, US, NATIONAL OBSERVATIONAL STUDY

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.1125-1126 [Peer Reviewed Journal]

2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-eular.701

Full text available

Citations Cited by
5
AB0539 IXEKIZUMAB TREATMENT RESPONSE: CONSISTENCY OVER TIME AND AT EACH VISIT IN PSORIATIC ARTHRITIS
AB0539 IXEKIZUMAB TREATMENT RESPONSE: CONSISTENCY OVER TIME AND AT EACH VISIT IN PSORIATIC ARTHRITIS
Material Type:
Article 		Add to My Research

AB0539 IXEKIZUMAB TREATMENT RESPONSE: CONSISTENCY OVER TIME AND AT EACH VISIT IN PSORIATIC ARTHRITIS

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.1301-1302 [Peer Reviewed Journal]

2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-eular.1514

Full text available

Citations Cited by
6
SAT0253 Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
SAT0253 Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
Material Type:
Article 		Add to My Research

SAT0253 Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.988 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.2000

Full text available

Citations Cited by
7
SAT0180 Two-year consolidated safety data for abp 501 in patients with moderate to severe rheumatoid arthritis
SAT0180 Two-year consolidated safety data for abp 501 in patients with moderate to severe rheumatoid arthritis
Material Type:
Article 		Add to My Research

SAT0180 Two-year consolidated safety data for abp 501 in patients with moderate to severe rheumatoid arthritis

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.951 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.6746

Full text available

Citations Cited by
8
POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMAL
POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMAL
Material Type:
Article 		Add to My Research

POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMAL

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1133-1134 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.1694

Full text available

Citations Cited by
9
FRI0090 MAINTENANCE OF CLINICAL RESPONSE WITH ABATACEPT IN COMBINATION WITH MTX IN INDIVIDUAL PATIENTS WITH EARLY RA WHO ARE MTX-NAÏVE AND ANTI-CITRULLINATED PROTEIN ANTIBODY (ACPA)+: RESULTS FROM THE INDUCTION PERIOD OF AVERT-2, A RANDOMISED PHASE IIIB STUDY
FRI0090 MAINTENANCE OF CLINICAL RESPONSE WITH ABATACEPT IN COMBINATION WITH MTX IN INDIVIDUAL PATIENTS WITH EARLY RA WHO ARE MTX-NAÏVE AND ANTI-CITRULLINATED PROTEIN ANTIBODY (ACPA)+: RESULTS FROM THE INDUCTION PERIOD OF AVERT-2, A RANDOMISED PHASE IIIB STUDY
Material Type:
Article 		Add to My Research

FRI0090 MAINTENANCE OF CLINICAL RESPONSE WITH ABATACEPT IN COMBINATION WITH MTX IN INDIVIDUAL PATIENTS WITH EARLY RA WHO ARE MTX-NAÏVE AND ANTI-CITRULLINATED PROTEIN ANTIBODY (ACPA)+: RESULTS FROM THE INDUCTION PERIOD OF AVERT-2, A RANDOMISED PHASE IIIB STUDY

Annals of the rheumatic diseases, 2020-06, Vol.79 (Suppl 1), p.623-623 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2020-eular.2367

Full text available

Citations Cited by
10
OP0165 A neoepitope fragment of c-reactive protein is prognostic of radiographic knee oa
OP0165 A neoepitope fragment of c-reactive protein is prognostic of radiographic knee oa
Material Type:
Article 		Add to My Research

OP0165 A neoepitope fragment of c-reactive protein is prognostic of radiographic knee oa

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.120 [Peer Reviewed Journal]

2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2017 © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2017-eular.6290

Full text available

Citations Cited by
11
FRI0388 SECUKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS, IRRESPECTIVE OF TIME SINCE FIRST DIAGNOSIS: POOLED RESULTS FROM THE SECUKINUMAB PHASE 3 TRIAL PROGRAM
FRI0388 SECUKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS, IRRESPECTIVE OF TIME SINCE FIRST DIAGNOSIS: POOLED RESULTS FROM THE SECUKINUMAB PHASE 3 TRIAL PROGRAM
Material Type:
Article 		Add to My Research

FRI0388 SECUKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS, IRRESPECTIVE OF TIME SINCE FIRST DIAGNOSIS: POOLED RESULTS FROM THE SECUKINUMAB PHASE 3 TRIAL PROGRAM

Annals of the rheumatic diseases, 2019-06, Vol.78 (Suppl 2), p.878-879 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2019-eular.2829

Full text available

Citations Cited by
12
AB0612 THE RELATIONSHIP BETWEEN SYSTEMATIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX (SLEDAI) AND HEALTHCARE RESOURCE UTILIZATION AND COSTS IN LUPUS PATIENTS
AB0612 THE RELATIONSHIP BETWEEN SYSTEMATIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX (SLEDAI) AND HEALTHCARE RESOURCE UTILIZATION AND COSTS IN LUPUS PATIENTS
Material Type:
Article 		Add to My Research

AB0612 THE RELATIONSHIP BETWEEN SYSTEMATIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX (SLEDAI) AND HEALTHCARE RESOURCE UTILIZATION AND COSTS IN LUPUS PATIENTS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1507-1507 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.2719

Full text available

Citations Cited by
13
AB1122 GUSELKUMAB VS GOLIMUMAB IN PSA TNFI-INADEQUATE RESPONDERS (EVOLUTION): FORMULATING A PRAGMATIC PHASE 3B RANDOMIZED TRIAL
AB1122 GUSELKUMAB VS GOLIMUMAB IN PSA TNFI-INADEQUATE RESPONDERS (EVOLUTION): FORMULATING A PRAGMATIC PHASE 3B RANDOMIZED TRIAL
Material Type:
Article 		Add to My Research

AB1122 GUSELKUMAB VS GOLIMUMAB IN PSA TNFI-INADEQUATE RESPONDERS (EVOLUTION): FORMULATING A PRAGMATIC PHASE 3B RANDOMIZED TRIAL

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1791-1791 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.876

Full text available

Citations Cited by
14
AB1108 EFFECT OF GUSELKUMAB ADMINISTERED EVERY 8 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS PERSISTS BETWEEN CONSECUTIVE DOSES AND IS DURABLE: POST HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
AB1108 EFFECT OF GUSELKUMAB ADMINISTERED EVERY 8 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS PERSISTS BETWEEN CONSECUTIVE DOSES AND IS DURABLE: POST HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Material Type:
Article 		Add to My Research

AB1108 EFFECT OF GUSELKUMAB ADMINISTERED EVERY 8 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS PERSISTS BETWEEN CONSECUTIVE DOSES AND IS DURABLE: POST HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1782-1783 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.642

Full text available

Citations Cited by
15
AB1099 SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR
AB1099 SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR
Material Type:
Article 		Add to My Research

AB1099 SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1775-1776 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.1671

Full text available

Citations Cited by
16
POS1051 SECUKINUMAB IMPROVES PHYSICAL FUNCTION AND INHIBITS STRUCTURAL DAMAGE IN PsA PATIENTS WITH SUSTAINED REMISSION OR LOW DISEASE ACTIVITY: RESULTS FROM A PHASE 3 STUDY
POS1051 SECUKINUMAB IMPROVES PHYSICAL FUNCTION AND INHIBITS STRUCTURAL DAMAGE IN PsA PATIENTS WITH SUSTAINED REMISSION OR LOW DISEASE ACTIVITY: RESULTS FROM A PHASE 3 STUDY
Material Type:
Article 		Add to My Research

POS1051 SECUKINUMAB IMPROVES PHYSICAL FUNCTION AND INHIBITS STRUCTURAL DAMAGE IN PsA PATIENTS WITH SUSTAINED REMISSION OR LOW DISEASE ACTIVITY: RESULTS FROM A PHASE 3 STUDY

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.803-804 [Peer Reviewed Journal]

2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-eular.1971

Full text available

Citations Cited by
17
POS0086 ANALYSIS OF DISEASE ACTIVITY MEASURES IN THE CONTEXT OF A METHOTREXATE WITHDRAWAL STUDY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB 11 MG ONCE DAILY + METHOTREXATE: POST HOC ANALYSIS OF DATA FROM ORAL SHIFT
POS0086 ANALYSIS OF DISEASE ACTIVITY MEASURES IN THE CONTEXT OF A METHOTREXATE WITHDRAWAL STUDY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB 11 MG ONCE DAILY + METHOTREXATE: POST HOC ANALYSIS OF DATA FROM ORAL SHIFT
Material Type:
Article 		Add to My Research

POS0086 ANALYSIS OF DISEASE ACTIVITY MEASURES IN THE CONTEXT OF A METHOTREXATE WITHDRAWAL STUDY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB 11 MG ONCE DAILY + METHOTREXATE: POST HOC ANALYSIS OF DATA FROM ORAL SHIFT

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.251-251 [Peer Reviewed Journal]

2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-eular.56

Full text available

Citations Cited by
18
POS1409 AUTOMATED DETECTION OF SCLERODERMIFORM PATTERNS USING CAPILLARY.IO
POS1409 AUTOMATED DETECTION OF SCLERODERMIFORM PATTERNS USING CAPILLARY.IO
Material Type:
Article 		Add to My Research

POS1409 AUTOMATED DETECTION OF SCLERODERMIFORM PATTERNS USING CAPILLARY.IO

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.987-988 [Peer Reviewed Journal]

2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-eular.4112

Full text available

Citations Cited by
19
POS0435 CHARACTERISTICS AND 6-MONTH OUTCOMES AMONG REAL-WORLD PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING UPADACITINIB: ANALYSIS FROM THE CORRONA REGISTRY
POS0435 CHARACTERISTICS AND 6-MONTH OUTCOMES AMONG REAL-WORLD PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING UPADACITINIB: ANALYSIS FROM THE CORRONA REGISTRY
Material Type:
Article 		Add to My Research

POS0435 CHARACTERISTICS AND 6-MONTH OUTCOMES AMONG REAL-WORLD PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING UPADACITINIB: ANALYSIS FROM THE CORRONA REGISTRY

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.446-446 [Peer Reviewed Journal]

2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-eular.170

Full text available

Citations Cited by
20
LB0004 EFFICACY AND SAFETY OF SECUKINUMAB IN ENTHESITIS-RELATED ARTHRITIS AND JUVENILE PSORIATIC ARTHRITIS: PRIMARY RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT WITHDRAWAL, PHASE 3 STUDY (JUNIPERA)
LB0004 EFFICACY AND SAFETY OF SECUKINUMAB IN ENTHESITIS-RELATED ARTHRITIS AND JUVENILE PSORIATIC ARTHRITIS: PRIMARY RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT WITHDRAWAL, PHASE 3 STUDY (JUNIPERA)
Material Type:
Article 		Add to My Research

LB0004 EFFICACY AND SAFETY OF SECUKINUMAB IN ENTHESITIS-RELATED ARTHRITIS AND JUVENILE PSORIATIC ARTHRITIS: PRIMARY RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT WITHDRAWAL, PHASE 3 STUDY (JUNIPERA)

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.201-202 [Peer Reviewed Journal]

2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-eular.5038

Full text available

Citations Cited by

Results 1 - 20 of 642  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
Refine
  1. Before 1998  (10)
  2. 1998 To 2003  (15)
  3. 2004 To 2009  (11)
  4. 2010 To 2015  (39)
  5. After 2015  (568)
  6. More options open sub menu

Language 

  1. Japanese  (2)
  2. Norwegian  (1)
  3. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait